Optogenetics, recognized by the 2026 medicine Nobel, makes cells respond to light, including eye cells that normally relay ...
A gene therapy based on Nobel prize-winning science has partially restored sight in some blind patients, with a clinical ...
The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...
Optogenetic therapy, based on Nobel prize-winning science, involves turning nerve cells on and off using light ...
Ultragenyx Pharmaceutical (RARE) is back in focus after the European Medicines Agency validated its Marketing Authorisation ...
Record global approvals, CRISPR breakthroughs, and expanding clinical and commercial activity are accelerating demand for cell and gene therapy tools and reagents.Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE ...
Aged beagle data hint at lower biological age and preliminary muscle changes with SIRT6c treatment, although key readouts ...
Andelyn Biosciences ("Andelyn"), a leading US-based patient-focused cell and gene therapy Contract Development and ...
An experimental treatment combining gene therapy with specialized goggles has helped some people with advanced blindness ...
The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as ...
Pharmaceutical Technology on MSN
Scientists claim Nobel Prize for approach behind light-activated gene therapy
The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, while pharma ...
Zacks Investment Research on MSN
Ultragenyx's gene therapy for Sanfilippo syndrome wins EMA validation
Ultragenyx Pharmaceutical RARE announced that the European Medicines Agency (EMA) has validated its Marketing Authorization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results